Glomerulonephritis Treatments

Find Glomerulonephritis Treatments

Brand Name

Benlysta

Generic Name

Belimumab

View Brand Information

FDA approval date: March 10, 2011

Classification: B Lymphocyte Stimulator-specific Inhibitor

Form: Injection, Solution

What is Benlysta (Belimumab)?

BENLYSTA is indicated for the treatment of: patients 5 years of age and older with active systemic lupus erythematosus who are receiving standard therapy, and, patients 5 years of age and older with active lupus nephritis who are receiving standard therapy. Limitations of Use The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system lupus. Use of BENLYSTA is not recommended in this situation. BENLYSTA is a B-lymphocyte stimulator -specific inhibitor indicated for the treatment of:, patients 5 years of age and older with active systemic lupus erythematosus who are receiving standard therapy; , patients 5 years of age and older with active lupus nephritis who are receiving standard therapy. Limitations of Use: The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system lupus. Use of BENLYSTA is not recommended in this situation.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Pilot Trial of Belimumab in Early Lupus

Who is this study for: Adult patients with Systemic Lupus Erythematous

Enrollment Status: Recruiting

Publish Date: June 12, 2026

Intervention Type: Biological, Other

Study Drug: Belimumab

Study Phase: Phase 4

Summary: This two year study will evaluate the effects of giving belimumab (Benlysta) to patients with Early Lupus. Early lupus is a diagnosis of lupus within 2 years. Subjects will be randomized to receive belimumab or placebo during the first year. During the second year, subjects who were randomized to belimumab will be rerandomized to continue to receive belimumab or to receive placebo. The study will ...

PRESERVE: A Multi-Center Phase 4 Study of the Efficacy and Safety of LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab at Inducing Rapid Renal Response in Patients With Lupus Nephritis

Enrollment Status: Recruiting

Publish Date: June 12, 2026

Intervention Type: Biological, Drug

Study Phase: Phase 4

Summary: The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).

A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus

Enrollment Status: Recruiting

Publish Date: June 03, 2026

Intervention Type: Biological

Study Phase: Phase 4

Summary: This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable first-line SLE therapy.

View All Clinical Trials

Related Latest Advances

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with a primary focus on rituximab and belimumab.

Journal: Expert opinion on biological therapy

Published: June 23, 2026

Comparing Efficacy and Safety of Various Monoclonal Antibodies in Myasthenia Gravis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

Journal: Brain and behavior

Published: June 17, 2026

Rapid early renal response to add-on belimumab in lupus nephritis.

Journal: Pediatric nephrology (Berlin, Germany)

Published: June 09, 2026

View All Latest Advances